Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) reflects the killing mechanism of antibodies through effector cells. The efficiency of this process depends on the Fcγ receptor (FcγR). Polymorphisms in these genes can change their activity. Here we are offering our customers ePBMC® with characterized FcγRIIIA loci, which can also be used as positive control for your assay.
About FcγRIIIa Polymorphism Characterized PBMC
Immune cells are able to recognize opsonized antigens via different Fcγ-Receptors. The receptor, which induces antibody dependent cell cytotoxicity (ADCC) is the FcγRIIIA receptor (CD16). This particular receptor recognizes clustered and bounded IgG. That recognition induces ADCC in the targeted cell. Polymorphisms in the receptor are suggested to enhance or reduce ADCC efficiency.
| ≥10 million cells per vial | Cat# CTL-GCP1 |
|---|
Please request for further information
Protocols
- Product Data Sheet Characterized Cryopreserved Human PBMC
- Thawing Cryopreserved PBMC
- Isolation of PBMC from Fresh Whole Blood
- Cryopreservation of PBMC from Fresh Whole Blood
- Plating PBMC into the ELISPOT Assay
Literature
- Resting of Cryopreserved PBMC Does Not Generally Benefit the Performance of Antigen-Specific T Cell ELISPOT Assays
- Optimal Thawing of Cryopreserved Peripheral Blood Mononuclear Cells for Use in High-Throughput Human Immune Monitoring Studies
- Brochure Cryopreserved Human PBMC
- Brochure Serum-free Media